Pregled bibliografske jedinice broj: 1176449
Mimosa action-opportunistic cervical cancer screening in Polyclinic Sunce
Mimosa action-opportunistic cervical cancer screening in Polyclinic Sunce // Abstracts of the 37th European Congress of Cytology ; u Cytopathology, vol. 23, suppl. 1 / Herbert, Amanda (ur.).
Oxford: Wiley-Blackwell, 2012. str. 104-104 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1176449 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Mimosa action-opportunistic cervical cancer
screening in Polyclinic Sunce
Autori
Ranogajec, Irena ; Moslavac, Sandra ; Jendriš Škrljak, Eva ; Vidović Gajger, Lovorka ;
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Abstracts of the 37th European Congress of Cytology ; u Cytopathology, vol. 23, suppl. 1
/ Herbert, Amanda - Oxford : Wiley-Blackwell, 2012, 104-104
Skup
37th European Congress of Cytology
Mjesto i datum
Cavtat, Hrvatska; Dubrovnik, Hrvatska, 30.09.2012. - 03.10.2012
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Cervical cancer ; Screening ; Pap smear ; Croatia
Sažetak
Aim: National days against cervical cancer, also known as Croatian Mimosa days is 21st of January. Every year preventive actions take place throughout Croatia and we show our results. Methods: In Polyclinic SUNCE Mimosa action extended from 21 January 2011 to 5 April 2011. In that period of time Pap smear was performed in 1774 women along with gynecological and ultrasound examination. Sixty percent of women were examined for the first time in our polyclinic and in 1627 (91.7%) of women were <55 years old. Results: In 1608 (90%) of women Pap tests were within normal limits. The cervical pathology was found in 166 (9.4%) of examined women with the following cytologic diagnoses: 90 (5%) atypical squamous cells (ASC), 50 (2.8%) cervical intraepithelial neoplasia (CIN I-III), 2 (0.11%) carcinoma in situ (CIS), 1 (0.05%) squamous cell carcinoma, 27(1.5%) atypical glandular cells (AGC) and 1 (0.05%) adenocarcinoma in situ (AIS). This action showed very good response in the short period of time but also indicated that women with abnormal results in the most cases were previously examined and treated and therefore wanted second opinion or follow-up control. Conclusion: The European Guidelines for cervical cancer screening recommend that cervical cancer screening should be offered through organized screening programmes. Accordingly, it would be necessary to organize and carry National screening programm in Croatia regard to Pap smear as a gold standard in cervical cancer diagnosis.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
